TechBio refers to life-sciences companies where software, data, and automation are core to the product — not an afterthought bolted onto traditional drug development.

How it works

Examples include AI-driven target discovery, cloud lab orchestration, CRISPR design tools, and diagnostics built on large multimodal datasets. Some TechBio firms license software to pharma; others run internal pipelines that produce drug candidates. Business models span SaaS subscriptions, usage-based lab fees, and milestone-heavy partnerships.

Investors compare TechBio to “biotech” (long FDA cycles, binary clinical outcomes) and “healthtech” (often care delivery or admin software). TechBio sits in the middle: deep science risk plus engineering velocity. Funding rounds may look like Series A software checks but diligence still covers IP, reproducibility, and regulatory path if therapeutics are in scope.

Why it matters

• Founders: Position clearly — platform vs pipeline. Mixed stories confuse investors on valuation comps and capital intensity.
• Investors: TechBio diligence blends technical diligence on models and lab validation with standard biotech IP review. Unit economics differ sharply between tool vendors and IND-stage programs.

Common mistake

Calling any biotech with a website “TechBio.” Without proprietary data loops, automation, or computational moats, the label adds no investor clarity.

Related ideas

See also TRL (Technology Readiness Level), technical diligence, synthetic biology, and computational drug discovery.